Core Viewpoint - Tilray Brands is struggling to achieve profitability despite its diverse product offerings in the beverage, cannabis, and wellness industries, with significant competition and ongoing losses impacting its financial performance [1][4]. Group 1: Financial Performance - Tilray Brands' stock price has decreased by 99% from its all-time high, reflecting investor fatigue over the company's inability to generate profits [4]. - The company has been expanding aggressively into other areas, particularly alcohol, but this strategy has not yet resulted in positive earnings [4]. Group 2: Revenue Growth and Strategy - Tilray is focusing on revenue growth through aggressive brand acquisitions since 2021, which has led to increased revenue and potential synergies [5]. - However, the rising share count due to stock sales for cash or acquisitions is diluting existing shareholders and complicating profit generation [6]. Group 3: Investment Risks - The ongoing losses and aggressive acquisition strategy present high risks for investors, with the company having to take write-downs across all divisions [7]. - Investors are advised to be cautious and may benefit from observing the company's performance before committing capital [7].

Core Viewpoint - The Cannabist Company has extended its forbearance agreement with senior noteholders, allowing them to defer exercising their rights until February 27, 2026, amidst ongoing financial negotiations [1][2]. Group 1: Forbearance Agreement - The Cannabist Company announced a further extension of the forbearance agreement with an ad hoc group of noteholders holding the Company's 9.25% Senior Secured Notes and 9.00% Senior Secured Convertible Notes, both due December 31, 2028 [1]. - The forbearance agreement allows noteholders to refrain from exercising their rights and remedies under the governing indenture and applicable law until February 27, 2026 [1]. Group 2: Company Overview - The Cannabist Company, formerly known as Columbia Care, is a prominent player in the cannabis industry, operating 69 facilities across 11 U.S. jurisdictions, including 54 dispensaries and 15 cultivation and manufacturing facilities [1]. - The company launched its retail brand, Cannabist, in 2021, establishing a national dispensary network that utilizes proprietary technology platforms [1]. - The Cannabist Company offers a diverse range of cannabis products, including flower, edibles, oils, and tablets, and manufactures several popular brands [1].

Core Viewpoint - Cannabis stocks have underperformed over the past five years, but recent positive regulatory changes in the U.S. may present long-term growth opportunities if the marijuana market expands significantly [1] Group 1: Canopy Growth - Canopy Growth is a leading player in the Canadian cannabis market with a diverse product portfolio, including dried cannabis flower, vapes, and edibles, and has a presence in multiple countries, including the U.S. [2] - Following President Trump's executive order to classify cannabis as a Schedule III substance, Canopy Growth may have expansion opportunities in the U.S. [3] - In Q3 2026, Canopy Growth reported net revenue of $54.62 million, a slight decrease of 0.3% year-over-year, but improved its net loss per share to $0.13 from $0.81 in the previous year [3] - If Canopy Growth can capitalize on U.S. opportunities and continue to reduce losses, it could yield strong returns [4] Group 2: Tilray Brands - Tilray Brands also has a comprehensive portfolio of cannabis products and operates in several countries, including the U.S., Germany, and Portugal, and has diversified into craft brewing and hemp-based products [5] - In Q2 of its 2026 fiscal year, Tilray reported net revenue of $217.5 million, a 3% year-over-year increase, while its net loss improved to $0.41 from $0.99 in the previous year [6] - Tilray is well-positioned to take advantage of emerging opportunities in the U.S. cannabis market, which could lead to significant share price increases if successful [6]

Core Insights - EnWave Corporation reported consolidated interim financial results for Q1 2026, showing significant revenue growth and improvements in gross margin compared to the previous year [1][4]. Financial Performance - Revenues for Q1 2026 reached CAD 1,600,000, an increase of 36% from CAD 1,177,000 in Q1 2025, attributed to large-scale machine sales and increased royalties [2][4]. - Direct costs rose to CAD 1,006,000, up 20% from CAD 837,000 in the prior year [2]. - Gross margin improved to CAD 594,000, representing a 75% increase from CAD 340,000, with a gross margin percentage of 37% compared to 29% in Q1 2025 [2][4]. - Operating expenses totaled CAD 1,468,000, a 16% increase from CAD 1,268,000, driven by higher sales personnel and other costs [2][4]. - The net loss from continuing operations was CAD 1,108,000, an 18% increase from CAD 938,000 in the previous year [2][4]. - Adjusted EBITDA loss was CAD 585,000, showing an improvement of CAD 50,000 from CAD 635,000 in Q1 2025 [2][4]. Revenue Breakdown - Base royalties for Q1 2026 were CAD 500,000, an 18% increase from CAD 425,000 in the prior year [4]. - Total royalty revenue for Q1 2026 was CAD 627,000, a 12% increase from CAD 559,000 in Q1 2025, driven by more royalty partners and increased product sales [4]. Corporate Developments - EnWave signed several Commercial License Agreements (CLAs) with partners, including Gowen Gumlu Grower's Association in Australia and Shinyway International Limited in New Zealand, indicating expansion in its market presence [10][11]. - The company has developed a robust intellectual property portfolio and continues to innovate in vacuum microwave dehydration technology, enhancing its competitive edge in the food, pharmaceutical, and cannabis industries [8][9].

Core Insights - The article discusses the launch and evolution of the 420 Investor service, which began in 2013, coinciding with Colorado's legalization of cannabis for adult use [1] - The service has transitioned to Seeking Alpha, continuing to provide extensive coverage of the cannabis sector, including model portfolios and educational materials for investors [1] - The Amplify Alternative Harvest ETF (MJ) was initially rated as a Sell, and it has since declined by nearly 33%, prompting a reconsideration of its status [1] Company Overview - Alan Brochstein, CFA, is highlighted as a pioneering investment professional in the cannabis industry, starting his career in the securities industry in 1986 [1] - He founded AB Analytical Services in 2007 to offer independent consulting to registered investment advisors and has been managing New Cannabis Ventures since 2015 [1] - The 420 Investor group, which focuses on publicly-traded cannabis stocks, has been operational since 2013 and includes features such as a model portfolio, weekly videos, summaries, and a monthly newsletter [1]

Analyst Recommendations - Stratus Properties has a rating score of 1.00, with one strong buy rating and one sell rating, while MJ has a rating score of 0.00 with no ratings [2]. Risk & Volatility - Stratus Properties has a beta of 1.28, indicating its share price is 28% more volatile than the S&P 500, while MJ has a beta of -0.18, indicating its share price is 118% less volatile than the S&P 500 [3]. Insider & Institutional Ownership - 61.6% of Stratus Properties shares are owned by institutional investors, and 10.0% are owned by insiders. In comparison, 35.9% of MJ shares are owned by insiders, suggesting stronger institutional confidence in Stratus Properties for long-term growth [4]. Earnings and Valuation - Stratus Properties reported gross revenue of $54.18 million, a price/sales ratio of 4.24, and a net income of $1.96 million, with an earnings per share of -$1.01 and a price/earnings ratio of -28.47. Stratus Properties has higher revenue and earnings compared to MJ [6]. Profitability - Stratus Properties has a net margin of -25.38%, a return on equity of -2.57%, and a return on assets of -1.46%. MJ's profitability metrics are not available [8]. Company Overview - Stratus Properties is a real estate company focused on the entitlement, development, management, leasing, and sale of residential and commercial properties primarily in the Austin, Texas area. MJ Holdings is a cannabis holding company involved in cultivation management and production of cannabis-related products in Nevada [10].

As filed with the Securities and Exchange Commission on February 19, 2026 Registration No. 333-292869 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 cbdMD, Inc. (Exact Name of Registrant As Specified In Its Charter) | North Carolina | 2833 | 47-3414576 | | --- | --- | --- | | (State Or Other Jurisdiction Of Incorporation Or Organization) | (Primary Standard Industrial | (I.R.S. Employer ...

Core Viewpoint - SNDL Inc. is set to release its fourth quarter and full year 2025 financial results on March 12, 2026, before market opening [1] Company Overview - SNDL Inc. is one of the largest vertically integrated cannabis companies in Canada and the largest private-sector liquor and cannabis retailer [2] - The company operates retail banners including Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf [2] - SNDL's consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future, and Bhang Chocolate [2] - The company aims to deploy strategic capital through direct and indirect investments and partnerships in the North American cannabis industry [2]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Curaleaf Holdings, Inc. due to lower revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - Curaleaf is expected to report a quarterly loss of $0.08 per share, reflecting a significant year-over-year change of -500% [3]. - Revenues are projected to be $327.84 million, which is a decrease of 1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 2.22% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Curaleaf is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -3.23% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with a strong predictive power for positive readings [7][8]. - Curaleaf's current Zacks Rank is 4, which complicates the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Curaleaf was expected to post a loss of $0.07 per share but actually reported a loss of -$0.06, resulting in a surprise of +14.29% [12]. - Over the past four quarters, Curaleaf has beaten consensus EPS estimates three times [13]. Conclusion - Curaleaf Holdings, Inc. does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].

Core Insights - Rubicon Organics has completed its first cannabis harvest at the new Cascadia facility, marking a significant operational milestone and demonstrating effective execution [2][3] - The new facility has increased Rubicon's premium production capacity by 40%, allowing the company to better meet domestic and international demand for premium cannabis [2][8] - The Cascadia facility is designed to support advanced cultivation technology and is expected to have an annual production capacity of up to 4,500 kg [4][8] Operational Developments - The facility was acquired in June 2025 and has undergone targeted capital investments, including layout modifications and new grow table installations to enhance efficiency [2][6] - Over 30 operations team members have been onboarded to support the facility's commercial production [2] - Initial harvests from Cascadia are expected to be monetized in Q2, with production quality anticipated to meet flagship-brand standards by mid-2026 [2] Strategic Positioning - Rubicon Organics is positioned as a leader in the premium cannabis segment, with a vertically integrated model and a portfolio of trusted brands [5][6] - The company aims to leverage its proprietary genetics and certifications for international distribution to capture growth in both domestic and export markets [6][7] - The disciplined execution and brand equity of Rubicon Organics contribute to steady revenue growth and positive Adjusted EBITDA [7]